GLP-1 Live Q&A with Dr. Stirrett: Ozempic, Tirzepatide, Retatrutide, and Microdosing
This live Q&A centers on GLP-1 medications—including Ozempic/semaglutide, Mounjaro and Zepbound/tirzepatide, and retatrutide—with a strong emphasis on using the lowest effective dose, protecting nutrition, and investigating stalls or fatigue rather than automatically increasing medication. Dr. Stirrett argues that many unwanted effects blamed on GLP-1s may stem from undereating, malnutrition, hormone changes, digestive issues, or unaddressed health factors. He also answers questions about injection sites, TRT, peptides, NAD+, alcohol, insurance, switching drugs, and surgery pauses.
1. Opening the Live Q&A
Dr. Stirrett opens by welcoming viewers from Seattle and inviting questions on GLP-1s, microdosing, hormone balance, weight loss, and related treatments. The format is informal: viewers submit personal situations in the chat, and he shares his general clinical perspective.
"If you guys have any questions for me whatsoever about GLP-1, microdosing, hormone balance, anything like that, throw it in the chat."
He begins with a subject he saw discussed on Instagram: "Ozempic personality." This phrase refers to people who report becoming emotionally flat, low-energy, low-mood, or depressed while taking GLP-1 drugs. Although he thinks the term is somewhat dramatized, he believes the pattern can be real—especially among people who arrive at his clinic already using GLP-1s at doses that may be too strong for them.
2. "Ozempic Personality" and the Risks of Undereating
Dr. Stirrett rejects the broad claim that drugs such as Ozempic, Zepbound, or Mounjaro inherently cause depression or emotional numbness. Instead, he frames these symptoms as a potential downstream consequence of overly aggressive appetite suppression.
"I don't think that's actually the case. I think there's a few things to consider."
His central explanation is straightforward: when a GLP-1 dose becomes too high, a person may lose hunger to the point that they cannot eat enough. If clinicians continue increasing the medication anyway, the result may be malnutrition—not necessarily in the extreme sense of starvation, but insufficient calories, protein, minerals, amino acids, and other nutrients needed for energy, recovery, and normal hormone production.
"If you're not getting in enough calories, you're not getting enough protein, nutrients, minerals, building blocks, amino acids across the board, it's going to kill your energy and your recovery, and it's going to kill your mood."
Hormones he would monitor
He particularly highlights two markers that, in his view, may be affected when someone is chronically under-fueling:
- Free T3, the active thyroid hormone
- Free testosterone
He explains that standard thyroid markers, such as TSH and T4, can look normal while the active thyroid hormone, free T3, may be low. In simple terms, T4 is often viewed as a more inactive "storage" form, while T3 is the form more directly involved in metabolic activity. He believes inadequate nutrition can reduce the body's ability to convert T4 into T3.
"If your T3 is low, that's what's establishing your metabolic rate."
A reduction in free T3, he says, can contribute to lower energy, a slower metabolism, poor mood, and an overall feeling of being "crummy." He similarly notes that free testosterone may decline even when total testosterone does not change much. Free testosterone is the portion not tightly bound to proteins and is generally considered more biologically available.
"The thyroid and the testosterone are literally like the two biggest things there from a hormone standpoint that can be impacted by malnutrition."
His basic message is that "Ozempic personality" may often be less about the drug's direct effect on personality and more about a person being pushed into an unsustainable degree of appetite suppression and nutritional depletion.
3. Calories and Protein as the Foundation
Dr. Stirrett says many people are given a GLP-1 prescription with little practical nutritional guidance beyond "make sure you eat enough." He stresses that "enough" differs among individuals, but he gives broad calorie levels that he personally views as warning signs:
- For many women, consistently eating below roughly 1,200 calories per day—and especially below 1,000—could raise concern for inadequate nutrition.
- For many men, consistently dropping below about 1,800 calories per day may be concerning.
These are presented as rough benchmarks rather than universal prescriptions. A person's size, age, activity, medical history, and goals all matter.
He places particular emphasis on protein, calling it one of the body's most important building blocks. Recalling an anti-aging conference, he says protein needs may increase with age because the body may become less efficient at digesting and using it.
"The older you are, the more you actually have to push and prioritize protein."
He mentions a conference benchmark of 100 grams of protein per day for people over 50, which he considers an excellent goal in an ideal situation. Yet he acknowledges that many people may only be getting around 40 grams daily, making a leap to 100 unrealistic at first.
"Maybe we can't go from 40 to 100, but let's do what we can to slowly ramp things up."
The practical takeaway is to prioritize sustainable improvements rather than perfection. In his approach, avoiding excessive dosage and maintaining adequate calories and protein are key ways to prevent fatigue, mood changes, and poor recovery during GLP-1 treatment.
4. GLP-1 Safety and Long-Term Monitoring
When a viewer says their doctor will not prescribe GLP-1 medication due to limited long-term testing, Dr. Stirrett responds that the broader GLP-1 drug class has existed for well over a decade, although semaglutide's popularity dramatically expanded its public visibility.
He considers these medications generally safe when used appropriately, but he also acknowledges a real limitation: no one can fully guarantee what any medication will do over the next 50 or 100 years.
"These are real therapies. It's not to be taken lightly."
Rather than treating GLP-1 drugs casually, he advocates regular laboratory work to monitor metabolic health, longevity-related markers, inflammation, hormone function, and potential adverse effects.
"We want to be running regular blood work… making sure that we're not doing more harm than good."
This is a recurring theme throughout the video: medication can be helpful, but treatment should include monitoring, nutrition, symptoms, digestion, and underlying health—not only weight on the scale.
5. Injection Sites, Plateaus, and Injection Reactions
Stomach, thigh, hip, and arm injections
A viewer asks whether moving injections from the stomach to the thigh can help break a weight-loss plateau. Dr. Stirrett says research suggests stomach injections may produce slightly stronger appetite suppression, but may also carry slightly more side effects.
For people using very low or "micro" doses, he usually prefers starting in the abdomen so they can still feel some therapeutic effect.
"I always have people start in the tummy for that reason unless there's site reactions or it gets irritated."
He has seen some people break a plateau after changing from the stomach to the thigh or side of the glute/hip, even though he does not know exactly why. He considers changing sites a reasonable experiment. Personally, he is not enthusiastic about thigh injections, based on his own extensive experience with injections, and he is also not a major fan of injections in the back of the arm.
Delayed injection-site irritation
For a person describing delayed injection-site reactions, he says that irritation is not usually directly related to a weight-loss stall. He suggests general precautions:
- Rotate injection sites
- Clean the skin carefully
- Consider whether the needle is being inserted too shallowly
- Discuss any persistent or concerning reaction with a qualified clinician
He explains that if an insulin needle deposits medication too close to the surface, it may remain in the upper skin layers and be more likely to irritate the area.
Later, when someone reports new injection-site irritation after reaching 10 mg, he raises questions about the source and handling of the medication—whether it is branded, compounded, from a reputable source, or potentially affected by a problematic vial. He says a new vial may sometimes be warranted, especially if contamination or a product issue is a concern.
6. Stalls: Why He Would Not Automatically Raise the Dose
Several viewers ask whether they should increase their tirzepatide or Zepbound dose after a slowdown in weight loss. Dr. Stirrett's repeated answer is that a plateau should trigger evaluation, not an automatic dose increase.
For a viewer using 5 mg of Zepbound, consuming about 1,200 calories and 100 grams of protein, and losing two pounds that month, he notes that they are still losing weight. Before moving to 7.5 mg, he would want to look at:
- Thyroid and hormone markers
- Inflammation
- Vitamin and nutrient status
- Digestive symptoms
- Constipation
- Food intake and overall calorie adequacy
He says constipation is especially important. If a person is not having regular bowel movements and is losing weight slowly, that may be a meaningful factor in the plateau.
"When it feels like you're doing everything right, that's typically when it's time to take a step back and do further evaluation."
For another viewer losing a significant amount of weight on an unconventional 2.9 mg dose every four to five days, he advises against increasing merely because a clinic protocol says it is time. In his framework, if someone is continuing to lose roughly 1.5 to 2.5 pounds per week, feels well, and is tolerating the drug, there may be no reason to increase.
"If you're losing weight… hold her there."
Lowest effective dose
This principle appears throughout the entire discussion:
"We still want to be a little bit hungry on these meds."
He believes complete appetite elimination makes it too difficult to nourish oneself. His goal is a dose that offers useful appetite support while still allowing the patient to consume adequate food, especially protein.
7. Dosing Frequency, Tolerance, and Microdosing
A viewer worries that 11 mg of tirzepatide may eventually stop working because a friend who has used it for three years no longer feels appetite suppression. Dr. Stirrett explains that the body may gradually adapt to any level of stimulation, whether someone is using a low dose or a high dose.
"That will happen at 1 mg and that will happen at 11 mg."
This is why he prefers using the lowest effective dose and making small adjustments only when needed. If someone starts high and later becomes tolerant, there is less flexibility to increase further. By contrast, smaller incremental changes may sometimes restore effects without a large jump in dose.
"A very, very small bump [may be enough] in order to re-initiate progress."
However, he also says that even when tolerance appears to develop, he does not always increase medication. He first looks at the broader "foundations":
- Nutrition and protein
- Exercise and lifestyle
- Supplements, where appropriate
- Hormones and blood work
- Digestion and bowel regularity
- Metabolic markers
The desired strategy is to combine a solid health foundation with small, carefully considered medication adjustments rather than relying solely on escalation.
Splitting weekly doses
One viewer asks about taking 3 mg three times per week rather than 9 mg once weekly, hoping to retain some hunger rather than feeling fully suppressed. Dr. Stirrett likes the underlying reasoning and says many of his patients inject twice weekly.
He believes divided dosing may create a smoother blood-level curve and avoid the "heavy hit" of one larger weekly dose.
"We don't want to shut it down all the way… because then it becomes very difficult to feed yourself."
Still, he emphasizes that the best schedule depends on the person's history, response, and prior dose stability.
8. Cycling and Switching GLP-1 Medications
A viewer reports cycling through tirzepatide, retatrutide, and Rybelsus, losing 45 pounds and finding it easier to eat protein on Rybelsus. Dr. Stirrett says he does not see anything inherently wrong with cycling GLP-1 medications, but his usual clinical preference is to select one therapy and remain consistent unless there is a reason to change.
A stall that cannot be resolved may be a reason to switch therapies. However, he does not consider switching automatically necessary when progress is good.
Tirzepatide versus semaglutide
When asked about changing from tirzepatide to semaglutide for financial reasons, he is supportive. He considers tirzepatide perhaps "a bit better" in some cases, but says the difference is not always dramatic in real-world outcomes.
"We used [semaglutide] for years, and we got phenomenal results."
"If you're going to switch from one to the other due to cost, I'd go right ahead."
He notes that semaglutide may be significantly cheaper, particularly through compounded options, though people should be mindful of medication source, prescription requirements, and clinician guidance.
When switching, he says semaglutide dosing is not directly comparable to tirzepatide: 0.25 mg semaglutide and 2.5 mg tirzepatide are entirely different starting points. Technically, a clinician may restart semaglutide near its standard starting dose, but someone coming from a moderate or high tirzepatide dose may feel little effect initially.
"Don't throw the baby out with the bathwater."
In other words, if the lowest semaglutide dose does not feel effective in the first week, do not immediately conclude that the medication will fail; appropriate titration may still be needed.
9. Digestive Effects: Constipation, Diarrhea, and Food Triggers
A viewer on 2.5 mg Zepbound reports intermittent diarrhea after several weeks. Dr. Stirrett says both constipation and diarrhea are common with GLP-1 medications.
He advises examining meals consumed roughly 8 to 12 hours before diarrhea episodes, paying special attention to:
- Heavy dairy intake
- Fried foods
- Restaurant meals
- Foods that are unusual for that individual
- Foods that may be inflammatory or poorly tolerated
He explains that GLP-1 medications slow stomach emptying and digestion. While this can clearly contribute to constipation, he believes delayed digestion can also worsen the impact of irritating foods, leading to diarrhea or a "flushing" response.
"It's sitting there, it's not being broken down as efficiently."
His general approach would be to investigate diet and digestive health first. Depending on the situation and prescribing arrangement, he says a lower dose may also be considered, but he does not rush to increase a medication when digestive symptoms are present.
10. Alcohol, Liver Markers, and GLP-1 Benefits Beyond Weight
A viewer from Spain says that after eight weeks on Mounjaro, they do not need much weight loss and do not struggle with overeating, but their alcohol intake has fallen substantially. Dr. Stirrett calls this a major potential benefit.
"The benefits of just simply not wanting the glass of wine or two at night is just outrageously beneficial."
He notes that people respond differently to alcohol. For some, even a few drinks each week can contribute to weight gain, poor metabolic health, or other issues—particularly in midlife. At the same time, he does not frame all alcohol use as automatically unacceptable. He says he wants patients to enjoy a lifestyle that feels meaningful and sustainable.
For someone drinking one or two glasses of wine nightly, he recommends discussing liver markers with a clinician, particularly:
- GGT (gamma-glutamyl transferase), a liver enzyme
- ALT
- AST
He says that although lab ranges may mark GGT values over 40 as abnormal, he personally prefers to see it below 30, and ideally below 20 alongside ALT and AST. In his view, persistent elevations may suggest that alcohol intake is too burdensome for the liver or that liver inflammation/fatty liver could be present.
"That would be your margin for safety, in my opinion."
Importantly, he says GLP-1 treatment may help metabolic health but does not make alcohol-related risks disappear.
11. Testosterone Replacement Therapy and Coming Off TRT
A viewer asks whether testosterone replacement therapy (TRT) must be lifelong and what criteria would support stopping it. Dr. Stirrett says his view differs from the common idea that "once on testosterone, always on testosterone."
During his clinical training, he saw testosterone used for people—men and women—who were depleted, exhausted, recovering poorly, and had low levels. In some cases, the goal was not permanent treatment but a temporary period of support while the person improved sleep, nutrition, exercise, muscle mass, and overall lifestyle.
"It does not need to be a forever therapy."
He says many people do choose to remain on TRT because they like its benefits. But he has also seen people stop treatment after improving their health habits and later find that their natural testosterone production recovered to a better level than before treatment.
Stopping TRT
He says he generally does not favor tapering testosterone itself, arguing that reducing the dose into a range below a person's natural needs may leave them feeling especially unwell.
"It's not good to taper off TRT… it will make you feel really sick."
For women, coming off may be simpler because doses are generally lower. For men, he says clinicians may use medications such as enclomiphene, or other therapies intended to stimulate LH (luteinizing hormone)—a signal that encourages the testicles to resume endogenous testosterone production. These decisions should be individualized and medically supervised, especially because TRT, fertility, hormone recovery, and prior anabolic steroid use can involve significant complexity.
12. Growth-Hormone Peptides: Sermorelin, Tesamorelin, and CJC/Ipamorelin
A viewer asks about stubborn belly fat and switching from sermorelin to tesamorelin after limited benefit. Dr. Stirrett explains that these are peptide-based therapies intended to influence growth-hormone signaling.
Sermorelin
He says sermorelin can increase growth hormone, but he is cautious about it for weight loss because it may also raise cortisol, which can in turn raise blood sugar. For people already metabolically vulnerable, he believes this may be counterproductive.
"For many, many people just trying to lose weight, Sermorelin usually is not the best option."
Tesamorelin
He considers tesamorelin potentially better but says the response can be highly variable. Based on his experience, some people report strong benefits, while many report little noticeable change, despite the therapy's expense.
CJC-1295 and ipamorelin
He says he has had more success with combinations such as CJC-1295 and ipamorelin, describing some patients as reporting improvements in performance and sleep. He shares an anecdote about a long-term patient with severe sleep difficulties who felt that ipamorelin/CJC was the only intervention that helped.
Still, these therapies are not presented as guaranteed answers. His wider message is that peptides should not replace foundational care.
"I don't like to over-peptide anybody."
Before layering on another peptide—such as MOTS-c, which he says he likes as an "icing on the cake"—he wants to ensure labs, hormones, nutrition, digestion, hydration, bowel regularity, supplements, and macronutrients are all addressed.
13. NAD+: Energy, Administration, and Limits
A viewer asks whether NAD+ provides energy or supports fat burning. Dr. Stirrett describes NAD as a molecule involved in cellular energy processes, helping cells produce ATP, the body's immediate usable energy currency.
"NAD is what's needed in the cell cycle. When it's inputted, it helps you produce ATP, or energy."
He says NAD production may decline with age, making supplementation attractive for some people. However, he is skeptical of many oral NAD supplements, believing they may be poorly absorbed or broken down in digestion. He prefers:
- Subcutaneous NAD injections
- Iontophoresis patches, which use a mild electrical system to drive compounds into the skin
He tells a personal story about giving his hospitalized grandfather an NAD patch shortly before his wedding in 2020. He attributes a sudden resurgence in his grandfather's energy to the patch, allowing him to attend the wedding.
"Ever since then I've been a massive believer in NAD."
This is an anecdotal personal experience rather than proof of a treatment effect, but it explains the speaker's enthusiasm. He also says that NAD is a prescription treatment in the form he considers "real NAD," whereas various liposomal or over-the-counter products are available but, in his opinion, less effective.
NAD combined with tirzepatide
When asked about compounded tirzepatide combined with NAD, he says he likes the concept and does not see why extra NAD would be harmful. But he strongly emphasizes that NAD is not the primary solution to GLP-1 fatigue.
"The best way to combat fatigue on a GLP-1 is not the NAD. It's dosage control."
His preferred first steps are keeping the GLP-1 dose low enough to preserve nutrition, ensuring adequate calorie intake, and obtaining blood work if fatigue persists despite eating enough.
14. Measuring Metabolic Progress Beyond Body Weight
For a viewer who has lost weight but still has a high body-fat percentage on a DEXA scan, Dr. Stirrett says he would not decide solely on whether to increase or decrease the GLP-1 dose. If weight loss is continuing and side effects are manageable, he typically maintains the current dose.
"If it's not broken, don't fix it."
He encourages tracking key metabolic markers every few months, including:
- Hemoglobin A1C, which reflects average blood sugar over roughly three months
- Fasting insulin
- Body-fat percentage
- Overall weight trend and symptoms
He names an insulin level around 5 and an A1C of around 5.0 to 5.2 as targets he uses when assessing whether insulin resistance has substantially improved.
Once metabolic markers and weight/body-composition goals are reached, he would consider slowly reducing to microdoses—often in small decreases every week or two, depending on the individual.
However, if someone still has around 10 pounds to lose, he says decreasing from a working dose to a much lower dose could stall progress. Again, the answer depends on the person's response, symptoms, goals, and metabolic data.
15. Insurance, Iron Infusions, Supplements, and Surgery
Insurance coverage
When asked how to obtain insurance coverage, Dr. Stirrett calls the system a "mess." Coverage often depends on a person's specific insurance plan and qualifying diagnoses, such as sleep apnea, prediabetes, or diabetes. He says prior authorizations are frequently denied and that he no longer handles them in his own practice because the success rate was so low.
"In nine out of 10 of them—or probably even more—[they] are denied."
He believes GLP-1 medications are becoming more affordable over time, particularly semaglutide, and says a lower-cost option may be worthwhile for someone who needs temporary support to improve metabolic health.
Iron infusions
Asked whether iron infusions reduce Mounjaro's effectiveness, he says he has not seen this as a direct problem. He notes that a temporary inflammatory reaction to iron could theoretically affect weight loss temporarily, but he does not regard iron infusion as a general contraindication to Mounjaro.
Existing supplements
When asked whether it is okay to keep taking supplements rather than discard them, he avoids giving a direct individualized answer. He does clarify later that he does not think NAD or tirzepatide would generally be a problem merely because a person is already using other supplements, though individual review is still sensible.
Pausing GLP-1s before surgery
A viewer asks whether someone stopping a GLP-1 for a month before surgery needs to taper the dose. Dr. Stirrett says he typically has people stop rather than taper, noting that many surgical pauses are only one to two weeks. He says the key issue is usually the interaction between slowed gastric emptying and anesthesia, not the medication's direct effect on healing.
"The only real contraindication… with surgery is the anesthesia."
He encourages patients to follow the surgeon's instructions and resume treatment when the surgical team considers it appropriate. He also acknowledges there may be surgical situations outside his expertise.
16. Closing Perspective
Dr. Stirrett ends by reiterating that his general approach to GLP-1 care is comprehensive rather than medication-only. His preferred strategy is to use the lowest effective dose, preserve hunger enough to support good nutrition, watch for signs of fatigue or hormone suppression, investigate stalls carefully, and use laboratory data to guide decisions.
"We want to maintain the lowest effective dosage… and not push past that."
Across the Q&A, the most consistent lesson is that weight loss is not the only outcome that matters. Energy, mood, digestion, protein intake, hormones, blood sugar, insulin resistance, liver health, and sustainable habits all deserve attention alongside the number on the scale.
Need a summary like this?
Get instant summaries with Harvest